EFFICACY AND SAFETY OF PYRONARIDINE TETRAPHOSPHATEARTESUNATE FOR TREATMENT OF UNCOMPLICATED Plasmodium falciparum MALARIA IN BINH PHUOC, GIA LAI AND PHU YEN PROVINCES, VIET NAM, IN 2021

From March to December 2021, this prospective, open-label, single-armobservational clinical trial, conducted in Binh Phuoc, Gia Lai and Phu Yen provinces,evaluated the safety and efficacy of oral Pyronaridine tetraphosphate-Artesunate oncedaily for three consecutive days in adults and children with microscopically confirmedP. falciparum malaria. Patients were treated as in-patients for Days 0–3, with followup visits on Days 7, 14, 21, 28, 35 and 42. The primary outcome was PCR-adjustedadequate clinical and parasitological response (ACPR) at Day 42. The results from 54P. falciparum patients has shown that: The efficacy of Pyronaridine tetraphosphate -Artesunate to P. falciparum has still high, with the rate of ACPR is 100%, the rate ofpositive parasitemia at day 3 is 50%, 54.5% and 54.8% in Binh Phuoc, Phu Yen andGia Lai, respectively. Pyronaridine-Artesunate is safety for the patients. None seriousadverd event are recorded.